Skip to main content

Table 1 Demographic and clinical characteristics of study participants

From: Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging

 

PLWoH (n=23)

PLWH on ART (n=25)

P value

Race; n (%)a

White

12 (52%)

13 (52%)

0.3880

Black

8 (35%)

9 (36%)

Other

1 (4%)

3 (12%)

White/Asian

2 (9%)

0 (0%)

Ethnicity; n (%)b

Hispanic

3 (13%)

3 (12%)

>0.99

Non Hispanic

20 (87%)

22 (88%)

Gender; n (%)b

Male

18 (78%)

21 (84%)

0.7195

Female

5 (22%)

4 (16%)

Sexual orinetation; n(%)a

Heterosexual

21 (91.3%)

7 (28%)

<0.0001

Homosexual/MSM

0 (0%)

18 (72%)

Unknown

2 (8.3%)

0 (0%)

Age; median (IQR)c

51 (11)

54 (13)

0.5901

BMI ; median (IQR)c

28.01 (4.54)

28.47 (10.545)

0.3811

BMI categorya

Normal Weight (<25), %

6 (26%)

6 (24%)

0.3026

Overweight (25-30), %

12 (52%)

8 (32%)

Obese (30-35), %

3 (13%)

4 (16%)

Morbidly Obese (>35), %

2 (9%)

7 (28%)

CD4 count (cells/mm3); median (IQR)

-

593 (395)

 

Nadir CD4 count (cells/mm3); median (IQR)

-

216 (227)

 

HIV load (copies/ml plasma); n (%)

Not detected

-

2 (8%)

 

<20

-

15 (60%)

<40

-

7 (28%)

41

-

1 (4%)

ART Regimen; n (%)

Elvitegravir (INSTI), Cobicistat, Emtricitabine (NRTI), Tenofovir alafenamide (NRTI)

-

2 (8%)

 

Bictegravir (INSTI), Emtricitabine (NRTI), Tenofovir alafenamide (NRTI)

-

11 (44%)

Abacavir (NRTI), Dolutegravir (INSTI), Lamivudine (NRTI)

-

3 (12%)

Emtricitabine (NRTI), Rilpivirine (NNRTI), Tenofovir alafenamide (NRTI)

-

4 (16%)

Dolutegravir (INSTI), Lamivudine (NRTI)

-

2 (8%)

Dolutegravir (INSTI), Doravirine (NNRTI)

-

1 (4%)

Dolutegravir (INSTI), Darunavir (PI), Cobicistat

-

1 (4%)

Dolutegravir (INSTI), Emtricitabine (NRTI), Tenofovir alafenamide (NRTI), Doravirine (NNRTI)

-

1 (4%)

Diabetes status; n (%)b

No

23 (100%)

21 (84%)

0.1105

Yes

0 (0%)

4 (16%)

Liver enzymes; median (IQR)c

AST (U/L)

19 (6)

24 (14.5)

0.0343

ALT (U/L)

20 (10)

23 (20.5)

0.0800

Hepatitis status; n (%)b

No

22 (96%)

17 (68%)

0.0045

Yes

0 (0%)

8 (32%)

Sub-Category :

Hx Hep C

0 (0%)

3 (12%)

 

Hx Hep B

0 (0%)

2 (8%)

Hx Hep A w/ coma

0 (0%)

1 (4%)

Others (e.g., fatty liver, alcoholic steatohepatitis

0 (0%)

2 (8%)

N/A

1 (4%)

0 (0%)

Neurological diseases status; n (%)b

No

20 (87%)

13 (52%)

0.0129

Yes

3 (13%)

12 (48%)

Gut diseases status; n (%)b

No

18 (78%)

13 (52%)

0.1246

Yes

5 (22%)

11 (44%)

Sub-Category :

GERD

5 (22%)

8 (32%)

 

Crohn's

0 (0%)

1 (4%)

Hx Candida esophagitis

0 (0%)

1 (4%)

Other (e.g., gastrectomy)

0 (0%)

1 (4%)

N/A

0 (0%)

1 (4%)

Heart diseases status; n (%)b

No

16 (70%)

6 (24%)

0.0033

Yes

7 (30%)

19 (76%)

Sub-Category :

Hypertension

2 (21.7%)

10 (40%)

 

Others (e.g., Tachycardia, High Blood pressure)

5 (8.7%)

9 (36%)

  1. aChi-sq test
  2. bFisher's exact Test
  3. cMann-Whitney U Test
Back to article page

Microbiome

ISSN: 2049-2618

Contact us